Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
50,153 articles
📰
S&P 500 No longer OVERVALUED
For the last 3 years or so (barring April 2025 tariffs), we’ve been hearing the S&P 500 was way overvalued. Now with a standard correction in the...
📰
Disney’s Stock Is A Dog
It does not seem like a new CEO has helped Disney (NYSE: DIS). Not even the anticipation that Josh D’Amaro will replace Bob Iger, who had an...
📰
Here's How Much You Would Have Made Owning Ciena Stock In The Last 5 Years
Ciena (NYSE:CIEN) has outperformed the market over the past 5 years by 38.82% on an annualized basis producing an average annual return of 48.95%....
Good Friday indeed
  submitted by   /u/owenchuah [link]   [comments]
Earplugs Market Size worth USD 2,218.29 Million by 2032, Exclusive Report by Maximize Market Research
PUNE, India, March 27, 2026 /PRNewswire/ -- According to Maximize Market Research, the global Earplugs Market is projected to grow from USD 1,464.97...
📰
Market Awaits Consumer Sentiment Data
Market Awaits Consumer Sentiment Data
📰
1 Underrated Reason to Invest in Amazon Stock
To be frank, the company's assets are an embarrassment of riches.
JPM's Michele: See Growth Slowdown, But Not Recession Amid $100 Oil
Bob Michele, JPMorgan Asset Management Global Head of Fixed Income, joins Bloomberg Surveillance to discuss current macroeconomic conditions amid the...
📰
Cybersecurity stocks plunge as Anthropic’s ‘Claude Mythos’ leak sparks AI fear
Cybersecurity stocks fell Friday, with CrowdStrike (NASDAQ:CRWD) dropping 7%, Palo Alto Networks (NASDAQ:PANW) declining 6%, Zscaler (NASDAQ:ZS) down...
Is CMTL Stock a Buy at 0.2x Sales? A Deep Dive at Catalysts and Risks
Comtech trades near 0.2x sales, but execution on modem ramps, backlog conversion and cash flow will determine if its margin recovery story holds.
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
Data presentations underscore category leadership and expertise in dermatology and immunology MUMBAI, India and PRINCETON, N.J., March 27, 2026...
Is CMTL Stock a Buy at 0.2x Sales? A Deep Dive at Catalysts and Risks
Comtech trades near 0.2x sales, but execution on modem ramps, backlog conversion and cash flow will determine if its margin recovery story holds.
Is CMTL Stock a Buy at 0.2x Sales? A Deep Dive at Catalysts and Risks
Comtech trades near 0.2x sales, but execution on modem ramps, backlog conversion and cash flow will determine if its margin recovery story holds.
Global Food Supply Faces a Dangerous Bottleneck as Iran War Persists
Fertilizer prices are climbing as a result of disruptions in the Middle East, putting global food supplies at risk.
📰
Up 58% in 2026, Is It Too Late to Buy Occidental Petroleum?
Occidental Petroleum (NYSE:OXY) has climbed 58% year-to-date, moving from $40.92 at the end of 2025 to $64.36 as of March 26. If you watched from the...
📰
Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking '1970s stagflation'
The economist and investor, known for calling the 2008 financial crisis, also said the “damage has already been done” to the economy.
📰
Anyone else been as foolish as me? A collection of painful and funny lessons from the stock market
Hey everyone, I’ve been trading for a few years now and looking back at some of my trades I can’t help but laugh and cry at the same time 😅 Blindly...
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?
Kodiak Sciences Inc (NASDAQ:KOD) shares are trading higher Friday morning after the company announced positive topline results from its Phase 3 GLOW2...
📰
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into...
📰
Every Cure’s drug repurposing strategy isn't what you think, and it could change rare disease treatment
When David Fajgenbaum and his colleagues launched the drug repurposing non-profit Every Cure, they chose a path that challenged the traditional...